Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
SIGNIFOR pasireotide 300 microgram/ 1 mL (as diaspartate) solution for injection ampoule, Accelagen (agent on behalf of the sponsor, Recordati Rare Diseases Australia), CON-419
Product name
SIGNIFOR pasireotide 300 microgram/ 1 mL (as diaspartate) solution for injection ampoule
Sponsor name
Accelagen (agent on behalf of the sponsor, Recordati Rare Diseases Australia)
ARTG
Consent start
Consent no.
CON-419
Standard
Paragraph 8(1)(i) and 10(5)(g) in the Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The productslabels state the sponsor is Novartis, which does not reflect the
current sponsorship of the product as Recordati Rare Diseases Australia Pty
Ltdpre-filled syringe diluent label of SIGNIFOR LAR does not include the
approved route of administration of the medicine
Therapeutic product type
Prescription medicines